Literature DB >> 8631794

The domain organization of human topoisomerase I.

L Stewart1, G C Ireton, J J Champoux.   

Abstract

Using limited proteolysis, we show that the domain boundaries of human topoisomerase I closely parallel those predicted from sequence comparisons with other cellular Topo I enzymes. The enzyme is comprised of (i) an NH2-terminal domain (approximately 24 kDa), which is known to be dispensable for activity, (ii) the core domain (approximately 54 kDa), (iii) a linker region (approximately 3 kDa), and (iv) the COOH-terminal domain (approximately 10 kDa), which contains the active site tyrosine. The highly conserved core and COOH-terminal domains are resistant to proteolysis, while the unconserved NH2-terminal and linker domains are sensitive. Noncovalent binding of Topo I to plasmid DNA or to short duplex oligonucleotides decreases the sensitivity of the linker to proteolysis by approximately a factor of 10 but has no effect on proteolysis of the NH2-terminal domain. When the enzyme is covalently complexed to an 18 base pair single-stranded oligonucleotide, the linker region is sensitive to proteolysis whether or not duplex DNA is present. The net positive charge of the linker domain suggests that at a certain point in catalysis the linker may bind directly to DNA. Further, we show that limited subtilisin cleavage can generate a mixture of 60-kDa core and approximately 10-kDa COOH-terminal fragments, which retain a level of topoisomerase activity that is nearly equal to undigested control samples, presumably because the two fragments remain associated after proteolytic cleavage. Thus, despite its potential role in DNA binding, the linker domain (in addition to the NH2-terminal domain) appears to be dispensable for topoisomerase activity. Finally, the limited proteolysis pattern of the human enzyme differs substantially from the limited proteolysis pattern of the vaccinia viral Topo I, indicating that the two enzymes belong to separate eukaryotic topoisomerase I subfamilies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8631794     DOI: 10.1074/jbc.271.13.7602

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.

Authors:  Yinghui Mao; Issac R Mehl; Mark T Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  A human topoisomerase I cleavage complex is recognized by an additional human topisomerase I molecule in vitro.

Authors:  K Søe; G Dianov; H P Nasheuer; V A Bohr; F Grosse; T Stevnsner
Journal:  Nucleic Acids Res       Date:  2001-08-01       Impact factor: 16.971

3.  DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein.

Authors:  James F Carey; Sharon J Schultz; Lisa Sisson; Thomas G Fazzio; James J Champoux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-23       Impact factor: 11.205

4.  Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro.

Authors:  Morten O Christensen; Hans U Barthelmes; Fritz Boege; Christian Mielke
Journal:  Nucleic Acids Res       Date:  2003-12-15       Impact factor: 16.971

5.  Free energy calculations reveal rotating-ratchet mechanism for DNA supercoil relaxation by topoisomerase IB and its inhibition.

Authors:  Jeff Wereszczynski; Ioan Andricioaei
Journal:  Biophys J       Date:  2010-08-04       Impact factor: 4.033

6.  Phosphorylation of serine residues in the N-terminal domains of eukaryotic type I topoisomerases.

Authors:  K Staron; D S Samuels
Journal:  Mol Biol Rep       Date:  1998-07       Impact factor: 2.316

7.  Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.

Authors:  Antonino Lauria; Mario Ippolito; Anna Maria Almerico
Journal:  J Mol Model       Date:  2006-10-28       Impact factor: 1.810

8.  8-Oxoguanine rearranges the active site of human topoisomerase I.

Authors:  Diem-Thu Thieu Lesher; Yves Pommier; Lance Stewart; Matthew R Redinbo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205

9.  Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.

Authors:  Giordano Mancini; Ilda D'Annessa; Andrea Coletta; Nico Sanna; Giovanni Chillemi; Alessandro Desideri
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

10.  Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum.

Authors:  César Ordóñez; Javier Alfonso; Rafael Balaña-Fouce; David Ordóñez
Journal:  J Biomed Biotechnol       Date:  2009-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.